|
|
|
|
|
|
Sponsors and Collaborators: |
Melbourne Health Sanofi-Aventis National Heart Foundation |
Information provided by: | Melbourne Health |
ClinicalTrials.gov Identifier: | NCT00232271 |
The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA).
People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat their condition.
Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies require the puncture of the leg veins . Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg.
It is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs
Condition | Intervention |
Deep Vein Thrombosis |
Drug: Clexane |
ChemIDplus related topics: | Enoxaparin Sodium |
Study Type: | Interventional |
Study Design: | Randomized, Single Blind, Placebo Control, Parallel Assignment |
Official Title: | The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation. |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Paul Sparks, MBBS,PhD, FRACP | 0393427000 ext 27133 | paul.sparks@mh.org.au |
Australia, Victoria | |||||
Royal Melbourne hospital | Recruiting | ||||
Melbourne, Victoria, Australia, 3050 | |||||
Contact: Paul Sparks, MBBS,PhD,FRACP 93427000 ext 27133 paul.sparks@mh.org.au | |||||
Contact: Fiona Sutherland 93427000 ext 27133 fiona.sutherland@mh.org.au | |||||
Principal Investigator: Paul Sparks, MBBS, PhD, FRACP |
Melbourne Health |
Sanofi-Aventis |
National Heart Foundation |
Principal Investigator: | Paul Sparks, MBBS, PhD. FRACP | Melbourne Health |
Study ID Numbers: | 2004-157 |
First Received: | October 2, 2005 |
Last Updated: | July 31, 2006 |
ClinicalTrials.gov Identifier: | NCT00232271 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
|
|
|
|